A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Treatment-Naive and Treatment-Experienced Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT I)
Latest Information Update: 18 Nov 2021
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms GIFT I
- Sponsors AbbVie
- 07 Mar 2018 Results of pooled data from nine clinical trials, were published in the Clinical Pharmacokinetics.
- 17 Jun 2016 Results assessing pharmacokinetics (n=257) published in the Clinical Pharmacokinetics
- 12 Mar 2016 Substudy results published in the Advances in Therapy